BridgeBio Pharma (BBIO) Work In Process (2025 - 2026)
BridgeBio Pharma recorded quarterly Work In Process of $10.5 million in Q1 2026, up 71.77% quarter-over-quarter from $6.1 million in Q4 2025, and up 695.52% year-over-year from $1.3 million in Q1 2025.
BridgeBio Pharma's Work In Process history runs 2 years deep, the most recent figure standing at $10.5 million for Q1 2026.
- In Q1 2026, Work In Process rose 695.52% year-over-year to $10.5 million; the TTM figure through Mar 2026 stood at $10.5 million (up 695.52% YoY), while the FY2025 annual figure was $6.1 million, changed N/A from the prior year.
- Work In Process came in at $10.5 million for Q1 2026 at BridgeBio Pharma, up from $6.1 million in the prior quarter.
- In the past five years, Work In Process ranged from a high of $10.5 million in Q1 2026 to a low of $1.1 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | BridgeBio Pharma | 12.91 Bn | 11.98 Bn | 184.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.49 Mn |
| Dec 31, 2025 | 6.10 Mn |
| Sep 30, 2025 | 4.13 Mn |
| Jun 30, 2025 | 1.07 Mn |
| Mar 31, 2025 | 1.32 Mn |